Výsledky vyhledávání - "Erwin R, Boghaert"

Akademický článek

Application of LDH assay for therapeutic efficacy evaluation of ex vivo tumor models

Autor: Megan C. Cox, Rita Mendes, Fernanda Silva, Teresa F. Mendes, Adelyn Zelaya-Lazo, Kathleen Halwachs, Julie J. Purkal, Inês A. Isidro, Ana Félix, Erwin R. Boghaert, Catarina Brito

Publikováno v: Scientific Reports, Vol 11, Iss 1, Pp 1-14 (2021)

Abstract The current standard preclinical oncology models are not able to fully recapitulate therapeutic targets and clinically relevant disease biology, evidenced by the 90% attrition rate of new therapies in clinical trials. Three-dimensional (3D)

Externí odkaz: https://doaj.org/article/6ba6021cf4734f4ebc89722a5ae55c02

Zobrazit plný text záznamu

Akademický článek

Pevonedistat and azacitidine upregulate NOXA (PMAIP1) to increase sensitivity to venetoclax in preclinical models of acute myeloid leukemia

Autor: Dan Cojocari, Brianna N. Smith, Julie J. Purkal, Maria P. Arrate, Jason D. Huska, Yu Xiao, Agnieszka Gorska, Leah J. Hogdal, Haley E. Ramsey, Erwin R. Boghaert, Darren C. Phillips, Michael R. Savona

Publikováno v: Haematologica, Vol 107, Iss 4 (2021)

Dysregulation of apoptotic machinery is one mechanism by which acute myeloid leukemia (AML) acquires a clonal survival advantage. B-cell lymphoma protein-2 (BCL2) overexpression is a common feature in hematologic malignancies. The selective BCL2 inhi

Externí odkaz: https://doaj.org/article/fcbff983b81140129e1223aefa05499e

Zobrazit plný text záznamu

Akademický článek

The Volume of Three-Dimensional Cultures of Cancer Cells In Vitro Influences Transcriptional Profile Differences and Similarities with Monolayer Cultures and Xenografted Tumors

Autor: Erwin R. Boghaert, Xin Lu, Paul E. Hessler, Thomas P. McGonigal, Anatol Oleksijew, Michael J. Mitten, Kelly Foster-Duke, Jonathan A. Hickson, Vitor E. Santo, Catarina Brito, Tamar Uziel, Kedar S. Vaidya

Publikováno v: Neoplasia: An International Journal for Oncology Research, Vol 19, Iss 9, Pp 695-706 (2017)

Improving the congruity of preclinical models with cancer as it is manifested in humans is a potential way to mitigate the high attrition rate of new cancer therapies in the clinic. In this regard, three-dimensional (3D) tumor cultures in vitro have

Externí odkaz: https://doaj.org/article/6657b2f38afc4560b02a1a64b41eee38

Zobrazit plný text záznamu

Pathophysiologic and Pharmacologic Considerations to Improve the Design and Application of Antibody–Drug Conjugates

Autor: Erwin R. Boghaert, Megan C. Cox, Kedar S. Vaidya

Publikováno v: Cancer Research. 82:1858-1869

Antibody–drug conjugates (ADC) have emerged as one of the pillars of clinical disease management in oncology. The biggest hurdle to widespread development and application of ADCs has been a narrow therapeutic index. Advances in antibody technologie

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::266b12108b15eac2d4db9fe316bd20c5
https://doi.org/10.1158/0008-5472.can-21-3236

Zobrazit plný text záznamu

Data from Targeting Multiple EGFR-expressing Tumors with a Highly Potent Tumor-selective Antibody–Drug Conjugate

Autor: Edward B. Reilly, Andrew M. Scott, Hui K. Gan, Thomas John, Puey-Ling Chia, Diana Cao, Joann P. Palma, Wenqing Gao, Erwin R. Boghaert, Kedar S. Vaidya, Anatol Oleksijew, Michael J. Mitten, Hugh D. Falls, Mark G. Anderson

ABBV-321 (serclutamab talirine), a next-generation EGFR-targeted antibody–drug conjugate (ADC) incorporates a potent pyrrolobenzodiazepine (PBD) dimer toxin conjugated to the EGFR-targeting ABT-806 affinity-matured AM1 antibody. ABBV-321 follows th

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::95d6b8106485307d7fd6d8f1fb1b654d
https://doi.org/10.1158/1535-7163.c.6542049

Zobrazit plný text záznamu

Data from ABT-414, an Antibody–Drug Conjugate Targeting a Tumor-Selective EGFR Epitope

Autor: Edward B. Reilly, Neal C. Goodwin, Laura M. McKay, Fritz G. Buchanan, Jonathan A. Meulbroek, Dong Cheng, Peter J. DeVries, Hugh D. Falls, Suzanne Norvell, Michael J. Mitten, Kedar S. Vaidya, Erwin R. Boghaert, Andrew C. Phillips

Targeting tumor-overexpressed EGFR with an antibody–drug conjugate (ADC) is an attractive therapeutic strategy; however, normal tissue expression represents a significant toxicity risk. The anti-EGFR antibody ABT-806 targets a unique tumor-specific

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7af9a53ea623c6dab8499fd2219a76bc
https://doi.org/10.1158/1535-7163.c.6538540.v1

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání